Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomalidomide plus low-dose dexamethasone vs high-dose dexamethasone in relapsed/refractory multiple myeloma
2010-019820-30Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Dec 2010
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pomalidomide in multiple myeloma (MM) (2 arms), sponsored by Celgene Corporation. Primary endpoint: progression-free survival. Started Dec 2010; status: completed.
02
Drugs
pomalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2010-019820-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019820-30.